Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Activation of innate immunity in primary human cells using a plant virus derived nanoparticle TLR7/8 agonist.

Carignan D, Herblot S, Laliberté-Gagné MÈ, Bolduc M, Duval M, Savard P, Leclerc D.

Nanomedicine. 2017 Nov 8. pii: S1549-9634(17)30195-8. doi: 10.1016/j.nano.2017.10.015. [Epub ahead of print]

PMID:
29128662
2.

A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.

Thérien A, Bédard M, Carignan D, Rioux G, Gauthier-Landry L, Laliberté-Gagné MÈ, Bolduc M, Savard P, Leclerc D.

J Nanobiotechnology. 2017 Jul 18;15(1):54. doi: 10.1186/s12951-017-0289-y.

3.

Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine.

Rioux G, Carignan D, Russell A, Bolduc M, Gagné MÈ, Savard P, Leclerc D.

J Nanobiotechnology. 2016 Jun 10;14(1):43. doi: 10.1186/s12951-016-0200-2.

4.

Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.

Carignan D, Thérien A, Rioux G, Paquet G, Gagné ML, Bolduc M, Savard P, Leclerc D.

Vaccine. 2015 Dec 16;33(51):7245-7253. doi: 10.1016/j.vaccine.2015.10.123. Epub 2015 Nov 6.

PMID:
26549362
5.

The size of the unbranched aliphatic chain determines the immunomodulatory potency of short and long chain n-alkanols.

Carignan D, Désy O, Ghani K, Caruso M, de Campos-Lima PO.

J Biol Chem. 2013 Aug 23;288(34):24948-55. doi: 10.1074/jbc.M113.466334. Epub 2013 Jul 9.

6.

Short-term immunological effects of non-ethanolic short-chain alcohols.

Désy O, Carignan D, de Campos-Lima PO.

Toxicol Lett. 2012 Apr 5;210(1):44-52. doi: 10.1016/j.toxlet.2012.01.005. Epub 2012 Jan 13. Review.

PMID:
22266471
7.
8.

Methanol induces a discrete transcriptional dysregulation that leads to cytokine overproduction in activated lymphocytes.

Désy O, Carignan D, Caruso M, de Campos-Lima PO.

Toxicol Sci. 2010 Oct;117(2):303-13. doi: 10.1093/toxsci/kfq212. Epub 2010 Jul 8.

PMID:
20616203
9.

Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators.

N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30.

Supplemental Content

Loading ...
Support Center